Funnel versus funnel-lite: the category’s loudest acquisition machine against a stripped-down version of the same aggressive-price playbook.
The two models
Hims is the category’s marketing heavyweight with its most contested model: after its Novo Nordisk partnership collapsed in June 2025, it leaned into “personalized” compounded semaglutide — the legal rationale regulators and manufacturers dispute most directly. Advertised entry prices are aggressive; true maintenance-dose totals are exactly what our pending verification exists to establish.
Remedy Meds markets aggressively on price while publishing comparatively little about its clinical workflow, pharmacy sourcing, and full fee stack — the documentation gap itself is the finding so far. It sits in our verification queue, and until that pass completes, no Remedy figure or score appears on this site.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Marketing gravity at two masses
Hims runs the full apparatus — brand, media spend, “personalization” framing; Remedy runs the compressed version — price-led ads, minimal published depth. The diligence is identical in kind and heavier for the smaller player: maintenance-dose truth, pharmacy sourcing, cancellation terms, all via documentation requests neither’s marketing volunteers. Ad weight is not evidence weight — and neither row in the ledger has figures until checkout says so.
Go deeper
Full files: Hims · Remedy Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.